NeuroSense Therapeutics

Business news, market intelligence, and global industry analysis.

The Latest

What the latest UTOPIA trial data reveal about UGN-103’s competitive position in LG-IR-NMIBC

Delivery Hero (DHER) stock up 4% to €29.5 as Aspex forces CEO exit and Korea sale opens

What the RIDGE-1 interim results reveal about the future of cardiac gene therapy in ARVC

Hanwha Aerospace targets NATO demand with Romania unmanned systems push at BSDA 2026

Representative image of scientists analyzing neurological data during amyotrophic lateral sclerosis research, reflecting the clinical investigation behind NeuroSense Therapeutics’ PrimeC therapy following the PARADIGM Phase 2b ALS trial publication in JAMA Neurology.

NeuroSense Therapeutics (NASDAQ: NRSN) advances PrimeC development after JAMA Neurology publishes PARADIGM Phase 2b ALS trial results

JAMA Neurology publishes PARADIGM trial results showing PrimeC slowed ALS decline. Discover what this means for NeuroSense Therapeutics’ Phase 3 plans.

μFR system
αvβ6-integrin
α4β7 integrin
Zywie Ventures
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures

March 16, 2026